Resveratrol para Atherosclerosis
C Evidências Evidência limitada de estudos de pequena dimensão, mas existem alguns sinais positivos.Improves FMD and reduces inflammatory markers. RESVACE trial was negative for cardiac function in heart failure. Bioavailability challenges limit clinical translation.
Conclusão
Improves FMD and reduces inflammatory markers. RESVACE trial was negative for cardiac function in heart failure. Bioavailability challenges limit clinical translation.
Key Study Findings
População: older adults and individuals with neurodegenerative disorders
População: review of age-related cardiac dysfunction and heart failure mechanisms
População: Review of anti-atherosclerotic supplements and bleeding
População: Atherosclerosis populations
População: None
População: None
Key Statistics
5
Estudos
400
Participantes
Positive
Nota
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosagens Comumente Utilizadas
- general:
- 150-500 mg/day
- cardiovascularsupport:
- 250-500 mg/day trans-resveratrol
Limite superior: Not formally established; GI discomfort common above 1,000 mg/day
Dosagens Estudadas em Pesquisas
| Dosagem | Duração | Efeito | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
Melhor horário: With meals; bioavailability enhanced by piperine co-supplementation
Safety & Side Effects
Efeitos Colaterais Relatados
- ⚠ Gastrointestinal discomfort (nausea, diarrhea, cramping) at high doses
- ⚠ Headache
- ⚠ May have estrogenic activity at high doses
Interações Conhecidas
- ● Anticoagulants (may inhibit platelet aggregation)
- ● CYP450 substrates (may inhibit CYP1A2, CYP3A4, CYP2D6)
- ● Blood pressure medications (additive hypotensive effect)
- ● Estrogen-sensitive conditions (weak estrogenic activity)
Ingestão máxima tolerável: Not formally established; GI discomfort common above 1,000 mg/day
Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.
Frequently Asked Questions
Does Resveratrol help with Atherosclerosis?
How much Resveratrol should I take for Atherosclerosis?
Are there side effects of Resveratrol?
How strong is the evidence for Resveratrol and Atherosclerosis?
Related Evidence
Outros ingredientes para Atherosclerosis
Resveratrol para outras condições
References
- [1] Lei Wang et al.. Phytother Res. 2026. Dietary Antioxidants, Polyphenols, and Vascular Health: Insights From Ultrasound Measurement of Carotid Intima-Media Thickness and Their Association With Cognitive Function … doi:10.1002/ptr.70198 PubMed
- [2] Zhuyubing Fang et al.. ESC Heart Fail. 2025. Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues. doi:10.1002/ehf2.14947 PubMed
- [3] Maria-Zinaida Dobre et al.. Int J Mol Sci. 2025. Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks. doi:10.3390/ijms262010183 PubMed
- [4] Shitian Guo et al.. Biomed Pharmacother. 2022. Resveratrol inhibiting TGF/ERK signaling pathway can improve atherosclerosis: backgrounds, mechanisms and effects. doi:10.1016/j.biopha.2022.113775 PubMed
- [5] Meiming Su et al.. Nutrients. 2022. Genome-Wide Transcriptional Profiling Reveals PHACTR1 as a Novel Molecular Target of Resveratrol in Endothelial Homeostasis. doi:10.3390/nu14214518 PubMed
- [6] Raúl Francisco Pastor et al.. Nutrients. 2020. Supplementation with Resveratrol, Piperine and Alpha-Tocopherol Decreases Chronic Inflammation in a Cluster of Older Adults with Metabolic Syndrome. doi:10.3390/nu12103149 PubMed
- [7] Wang Anlu et al.. Pharmacol Res. 2019. Using herbal medicine to target the "microbiota-metabolism-immunity" axis as possible therapy for cardiovascular disease. doi:10.1016/j.phrs.2019.02.018 PubMed
- [8] Michał Wiciński et al.. Nutrients. 2018. Beneficial Effects of Resveratrol Administration-Focus on Potential Biochemical Mechanisms in Cardiovascular Conditions. doi:10.3390/nu10111813 PubMed
- [9] A Tressera-Rimbau et al.. Oxid Med Cell Longev. 2017. Dietary Polyphenols in the Prevention of Stroke. doi:10.1155/2017/7467962 PubMed
- [10] Enrico Gugliandolo et al.. Pharmacol Res. 2017. Palmitoylethanolamide and Polydatin combination reduces inflammation and oxidative stress in vascular injury. doi:10.1016/j.phrs.2017.06.014 PubMed
- [11] Ling Zhao et al.. Nutr Rev. 2011. Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals. doi:10.1111/j.1753-4887.2011.00394.x PubMed
- [12] Alberto A A Bertelli et al.. J Cardiovasc Pharmacol. 2009. Grapes, wines, resveratrol, and heart health. doi:10.1097/FJC.0b013e3181bfaff3 PubMed
Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.